A novel therapy targeting γ-aminobutyric acid is safe and may be effective in major depressive disorder

1. H3-10353, a novel γ-aminobutyric acid (GABA) positive allosteric modulator, is safe and well-tolerated in healthy patients and those with major depressive disorder (MDD), and demonstrated some therapeutic benefits in a phase 1 clinical trial. Evidence Rating Level: 1 (Excellent) Although there are numerous classes of medications for depression, these treatments result in remission in […] The…